- Stocks
- Pharma & Healthcare
- Blue Jet Healthcare
Blue Jet Healthcare share price
NSE: BLUEJETPharma & HealthcareBiotechnology
Blue Jet Healthcare at a glance
Blue Jet Healthcare (NSE: BLUEJET) closed at ₹499.60 on 22 Oct 2026, up 1.50% on the day. With a market capitalisation of ₹9,456 Cr, it ranks 564th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 35× trailing earnings, against a return on equity of 40.7% in FY21. Over the past year the share price has fallen 23.8%. Its 52-week range is ₹325.00 (30 Mar 2026) to ₹688.50 (4 Nov 2025); the last close is 27.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹293 Cr (−17.4% year on year) and net profit ₹78 Cr (−14.2%), on a standalone basis. Promoters held 73.15% of the company as of 9 Jul 2026.
Key numbers
- Market cap
- ₹9,456 CrRank 564 on NSE
- P/E (trailing)
- 35×
- Price to book
- 0×FY21
- EPS (TTM)
- ₹13.55to Q1 FY27
- ROE
- 40.7%FY21
- ROCE
- 52.3%FY21
- Debt to equity
- 0.11FY21
- Net profit margin
- 27.2%FY21
- Book value / share
- ₹3,428.34FY21
- 52-week high
- ₹688.504 Nov 2025
- 52-week low
- ₹325.0030 Mar 2026
- 1-year return
- −23.8%
- RSI (14-day)
- 31.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.50% | −3.9% | −14.1% | −14.5% | −23.8% |
Blue Jet Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹208 Cr | ₹318 Cr | ₹340 Cr | ₹355 Cr | ₹165 Cr | ₹192 Cr | ₹235 Cr | ₹293 Cr |
| Revenue YoY | +14.8% | +90.9% | +85.1% | +117.8% | −20.5% | −39.6% | −31.1% | −17.4% |
| Net profit | ₹58 Cr | ₹99 Cr | ₹110 Cr | ₹91 Cr | ₹52 Cr | ₹40 Cr | ₹64 Cr | ₹78 Cr |
| Net profit YoY | +21.9% | +208.3% | +178.8% | +141.3% | −10.6% | −59.4% | −41.6% | −14.2% |
| Net margin | 28.0% | 31.1% | 32.3% | 25.7% | 31.5% | 20.9% | 27.4% | 26.7% |
| EPS | ₹3.36 | ₹5.71 | ₹6.35 | ₹5.26 | ₹3.01 | ₹2.32 | ₹3.71 | ₹4.51 |
Blue Jet Healthcare financials
| Item | FY20 | FY21 |
|---|---|---|
| Revenue | ₹538 Cr | ₹499 Cr |
| Operating profit | ₹194 Cr | ₹190 Cr |
| Net profit | ₹145 Cr | ₹136 Cr |
| EPS (₹) | ₹1,463.00 | ₹1,396.00 |
| Cash from operations | ₹123 Cr | ₹131 Cr |
| Total debt | ₹37 Cr | ₹29 Cr |
| Shareholders' equity | ₹192 Cr | ₹340 Cr |
Blue Jet Healthcare shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 | 9 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 86.00% | 79.81% | 79.81% | 79.81% | 79.81% | 73.15% |
| Foreign institutions | 1.97% | 1.82% | 1.14% | 0.88% | 0.40% | 0.62% |
| Domestic institutions | 0.94% | 3.63% | 4.65% | 4.51% | 4.65% | 9.12% |
| Non-institutions | 11.09% | 14.74% | 14.41% | 14.80% | 15.14% | 17.11% |
Blue Jet Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Blue Jet Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| METROPOLISMetropolis Healthcare | ₹532.25 | −0.03% | +9.2% | ₹11,035 Cr | 57.9 | — |
| AKUMSAkums Drugs and Pharmaceuticals | ₹690.85 | −0.17% | +50.2% | ₹10,874 Cr | 41.5 | — |
| PARKHOSPSPark Medi World | ₹220.45 | −0.74% | — | ₹9,522 Cr | 32.1 | — |
| BLUEJETBlue Jet Healthcare | ₹499.60 | +1.50% | −23.8% | ₹9,456 Cr | 35 | — |
| VIYASHViyash Scientific | ₹214.90 | −0.05% | +3.1% | ₹9,388 Cr | 53.6 | — |
| STARStrides Pharma Science | ₹1,017.30 | −1.23% | +27.8% | ₹9,377 Cr | 16.9 | — |
| YATHARTHYatharth Hospital & Trauma Care Services | ₹932.10 | +1.22% | +14.4% | ₹8,981 Cr | 51.2 | — |
Ask anything about Blue Jet Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against BLUEJET's own history. Try: “Why has BLUEJET moved over the last three months?” · “Backtest a 50-day moving-average crossover on BLUEJET over five years” · “Compare BLUEJET with METROPOLIS on margins and valuation”
Frequently asked questions about Blue Jet Healthcare
What is the share price of Blue Jet Healthcare today?
Blue Jet Healthcare (NSE: BLUEJET) last closed at ₹499.60 on 22 Oct 2026. Its 52-week high is ₹688.50 and its 52-week low is ₹325.00.
What is the market cap of Blue Jet Healthcare?
Blue Jet Healthcare's market capitalisation is ₹9,456 Cr (₹9,456 Cr) at the 22 Oct 2026 close, ranking 564th among the NSE companies Pivot tracks.
What is the P/E ratio of Blue Jet Healthcare?
Blue Jet Healthcare trades at a trailing P/E of 35. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 51.2.
What is the ROE and ROCE of Blue Jet Healthcare?
Return on equity was 40.7% in FY21 and return on capital employed was 52.3% in FY21 (consolidated figures).
Is Blue Jet Healthcare a debt-free company?
No. Blue Jet Healthcare's debt-to-equity ratio was 0.11 in FY21, with total debt of ₹29 Cr.
What were Blue Jet Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Blue Jet Healthcare reported revenue of ₹293 Cr, −17.4% year on year, and net profit of ₹78 Cr, −14.2% year on year.
How has Blue Jet Healthcare stock performed over the last year?
Blue Jet Healthcare's share price has fallen 23.8% over the past year, −14.5% over three months and −14.1% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Blue Jet Healthcare?
As of 9 Jul 2026: promoters 73.15%, foreign institutions 0.62%, domestic institutions 9.12%, non-institutions 17.11%.
Who are Blue Jet Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Blue Jet Healthcare by market cap are Metropolis Healthcare, Akums Drugs and Pharmaceuticals, Park Medi World, Viyash Scientific, Strides Pharma Science and Yatharth Hospital & Trauma Care Services.
Is Blue Jet Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Blue Jet Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BLUEJET against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text